NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced the pricing of its previously announced underwritten public offering of an aggregate of 11,250,000 shares of its common stock at an offering price of $4.00 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 3,750,000 shares of common stock at an offering price of $3.999 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant.

2024年6月13日，纽约（环球通讯社）--Rezolute，Inc.（纳斯达克：RZLT）（“Rezolute”或“公司”）是一家致力于开发针对严重罕见疾病的新型转化疗法的晚期生物制药公司，今天宣布，其先前宣布的包销公开发行定价为11250000股普通股，发行价格为每股4.00美元，并向某些投资者提供了预付认股权证，以购买多达3750000股普通股，发行价格为每股3.999美元，相当于普通股的每股发行价减去每股0.001美元每个预先出资权证的行权价格。

Gross proceeds from the underwritten public offering before deducting underwriting discounts and commissions and other offering expenses are expected to be approximately $60 million. All shares of common stock and pre-funded warrants to be sold in the offering will be offered by Rezolute. The closing of the offering is expected to occur on or about June 17, 2024, subject to the satisfaction of customary closing conditions.

在扣除承销折扣和佣金以及其他发行费用之前，承销公开发行的总收益预计约为6000万美元。本次发行中出售的所有普通股和预支认股权证将由Rezolute发行。预计本次发行将于2024年6月17日左右结束，但须符合惯例的结束条件。

Jefferies and Cantor are acting as the joint book-running managers for the offering. BTIG, Craig-Hallum, H.C. Wainwright & Co., Jones and Maxim Group LLC are acting as co-managers for the offering. A shelf registration statement on Form S-3 (File No. 333-275562) relating to the securities to be offered in the public offering was filed with the Securities and Exchange Commission (the “SEC”) and was declared effective on November 29, 2023.

Jefferies和Cantor担任此次发售的联合账簿管理人。BTIG、Craig Hallum、H.C.Wainwright&Co.、Jones和Maxim Group LLC担任此次发售的联合管理人。与公开发售中发售的证券有关的S-3表格（文件号333-275562）的货架登记声明已提交给证券交易委员会（“SEC”），并于2023年11月29日宣布生效。

The public offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus has been filed with the SEC an.

本次公开发行将仅通过补充招股说明书和作为登记声明一部分的随附招股说明书进行。初步招股说明书已提交给SEC an。